LENZ · LENZ Therapeutics, Inc.

LENZ Therapeutics’ Q1 2026 results reflect the company’s transition from development to commercial operations following the July 2025 FDA approval of VIZZ. The $1.7 million in product sales—driven by ~25,000 paid prescriptions—represents early but measurable launch momentum, with a 19% sequential increase from Q4 2025. Total revenue of $1.9 million includes $0.2 million in license revenue from the Lunatus Middle East distribution agreement, underscoring progress in international commercialization. However, the $41.5 million net loss reflects aggressive, planned commercial investment: SG&A surged to $45.0 million (versus $11.1 million in Q1 2025), primarily due to marketing, advertising, sales force expansion (from 88 to 117 territories), and personnel costs. Notably, R&D expenses fell to zero, confirming the shift away from clinical development. Cost of sales ($1.1 million) was largely non-recurring—tied to a manufacturing process transition—not direct product cost, which remained immaterial. Management emphasized real-world efficacy, strong ECP adoption (>10,000 prescribers, 60% repeat prescribing), and consumer engagement via the Sarah Jessica Parker DTC campaign. With $258.4 million in cash and marketable securities as of March 31, 2026, LENZ maintains a robust runway to execute its U.S. launch and advance ex-U.S. regulatory filings—including recent MAA submissions to the EMA and MHRA—and partnership strategy. No forward guidance was provided in the filing or press release.